PE Anti-FTO antibody [EPR6895],Abcam,AB318376

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Host

Rabbit

Reactivity

Human

Application

Target Binding Affinity, IHC-P, Antibody Labelling

Conjugate

PE

Platform ID

BAB987471517

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NamePE Anti-FTO antibody [EPR6895]
Cat. No.AB318376
HostRabbit
IsotypeIgG
ReactivityHuman
ConjugationPE
ApplicationTarget Binding Affinity, IHC-P, Antibody Labelling
ClonalityMonoclonal
Clone NumberEPR6895
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data RNA demethylase that mediates oxidative demethylation of different RNA species, such as mRNAs, tRNAs and snRNAs, and acts as a regulator of fat mass, adipogenesis and energy homeostasis (PubMed : 22002720, PubMed : 25452335, PubMed : 26457839, PubMed : 26458103, PubMed : 28002401, PubMed : 30197295). Specifically demethylates N(6)-methyladenosine (m6A) RNA, the most prevalent internal modification of messenger RNA (mRNA) in higher eukaryotes (PubMed : 22002720, PubMed : 25452335, PubMed : 26457839, PubMed : 26458103, PubMed : 30197295). M6A demethylation by FTO affects mRNA expression and stability (PubMed : 30197295). Also able to demethylate m6A in U6 small nuclear RNA (snRNA) (PubMed : 30197295). Mediates demethylation of N(6),2'-O-dimethyladenosine cap (m6A(m)), by demethylating the N(6)-methyladenosine at the second transcribed position of mRNAs and U6 snRNA (PubMed : 28002401, PubMed : 30197295). Demethylation of m6A(m) in the 5'-cap by FTO affects mRNA stability by promoting susceptibility to decapping (PubMed : 28002401). Also acts as a tRNA demethylase by removing N(1)-methyladenine from various tRNAs (PubMed : 30197295). Has no activity towards 1-methylguanine (PubMed : 20376003). Has no detectable activity towards double-stranded DNA (PubMed : 20376003). Also able to repair alkylated DNA and RNA by oxidative demethylation : demethylates single-stranded RNA containing 3-methyluracil, single-stranded DNA containing 3-methylthymine and has low demethylase activity towards single-stranded DNA containing 1-methyladenine or 3-methylcytosine (PubMed : 18775698, PubMed : 20376003). Ability to repair alkylated DNA and RNA is however unsure in vivo (PubMed : 18775698, PubMed : 20376003). Involved in the regulation of fat mass, adipogenesis and body weight, thereby contributing to the regulation of body size and body fat accumulation (PubMed : 18775698, PubMed : 20376003). Involved in the regulation of thermogenesis and the control of adipocyte differentiation into brown or white fat cells (PubMed : 26287746). Regulates activity of the dopaminergic midbrain circuitry via its ability to demethylate m6A in mRNAs (By similarity). Plays an oncogenic role in a number of acute myeloid leukemias by enhancing leukemic oncogene-mediated cell transformation : acts by mediating m6A demethylation of target transcripts such as MYC, CEBPA, ASB2 and RARA, leading to promote their expression (PubMed : 28017614, PubMed : 29249359). See full target information FTO

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.